"This major commitment from the Indiana Seed Fund makes it possible for us to move our research and ideas forward," said Paul Hall, President and CEO of Bioscience Vaccines, Inc.  "This new funding starts us on the road to realizing great advancements in the prevention and treatment of a wide range of serious diseases, with life-improving and life-saving results."

By 2012, human vaccines are expected to be a $24 billion market, and the veterinary vaccine market accounts for another $4 to $5 billion.  One hundred million H1N1 doses were approximated to be given in the U.S. alone in 2009.

Dr. Suckow, a founding scientist of Bioscience Vaccines, Inc. and associate research professor in the department of biological sciences at the University of Notre Dame, sees Bioscience Vaccines as an important opportunity for the ECM technology.  "While a pathogen protein approach makes vaccines purer, safer and quicker to produce, it also increases the need for adjuvants to ensure efficacy.  We believe that our ECM-based product can be formulated for use with vaccine products already being used for the prevention of specific human diseases.  There is also potential for the product to be used by the U.S. Department of Agriculture for the prevention of animal diseases."

"By having Bioscience Vaccines as an exclusive licensee, they will be able to focus their ECM research and development on the specialized area of vaccines," said Mark Bleyer, President, Cook Biotech and member of Bioscience Vaccines' Board of Directors.

The company is currently in discussions to locate its headquarters at Innovation Park at Notre Dame in South Bend, IN.

SOURCE BioCrossroads